Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced results from the landmark myCare-040 clinical study, which demonstrates the predictive capability of the Cellworks Platform in guiding chemotherapy treatment decisions for patients with metastatic non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). The findings advance a personalized approach to NSCLC treatment selection that maximizes benefit and minimizes unnecessary toxicity.

Results from the myCare-040 study were showcased in a poster presentation titled, Computational Modeling of Comprehensive Genomic Profiling to Predict Chemotherapy Benefit in Advanced NSCLC, as part of the IASLC 2025 World Conference on Lung Cancer (#WCLC25) hosted by the International Association for the Study of Lung Cancer taking place September 6-9, 2025 at the Fira de Barcelona Convention Center Gran Via in Barcelona, Spain.

“Although combination chemo-immunotherapy remains a standard first-line option for advanced NSCLC, the incremental benefit of adding chemotherapy varies substantially among patients,” said Charu Aggarwal, MD, MPH, FASCO, Leslye M. Heisler Professor of Lung Cancer Excellence in the Perelman School of Medicine at the University of Pennsylvania, and Co-Principal Investigator of the study. “The findings from this study reveal a novel personalized computational biosimulation approach capable of identifying patients most likely to benefit from combination chemo-immunotherapy rather than immunotherapy alone, thereby reducing exposure to treatment-related toxicities in those unlikely to respond. This innovation constitutes an important advancement in personalized therapy selection for NSCLC.”

“The use of broad-based molecular testing has helped identify patients with actionable biomarkers who may benefit from targeted therapies,” said Tejas Patil, MD, Assistant Professor of Medicine-Medical Oncology, University of Colorado School of Medicine, and Co-Principal Investigator of the study. “In particular, PD-L1 testing has gained relevance as an important biomarker in determining the role of immune checkpoint inhibitors, especially for those patients whose PD-L1 expression levels are 50% or greater. However, we also know that this is an imperfect biomarker and does not capture the full spectrum of which patients may benefit from chemotherapy with immune checkpoint inhibitors. In this study, we utilized Cellworks computational modeling to determine which patients receiving first line cancer treatment would benefit from the addition of chemotherapy with immune checkpoint inhibitors. This represents a clinically meaningful step forward in personalized medicine for NSCLC.”

“While PD-L1 expression is widely used to guide treatment decisions in NSCLC, it is not a reliable predictor of chemo-immunotherapy benefit,” said James Wingrove, PhD, Chief Development Officer at Cellworks. “Chemo-immunotherapy response depends on complex interactions between tumor biology and the immune system—far more than any single biomarker, including PD-L1, can capture. In this study, we leveraged NGS and biosimulated tumor behavior to deliver a personalized prediction of each patient’s likelihood of responding to chemo-immunotherapy versus immunotherapy alone. This approach offers a level of personalization that PD-L1 alone simply cannot provide.”

To address the variability in chemotherapy benefit among patients with advanced NSCLC, Cellworks developed a mechanistic computational biology model (CBM) that uses tumor-specific genomic data obtained through NGS. The model maps signaling pathway dysregulation to predict how a patient will respond to immune checkpoint inhibitor (ICI) therapy alone or in combination with chemotherapy (ICI+C).

Source: businesswire.com